Patient Registry
OtherPatient Registry
NCT Number: NCT07385443
Myotonic Dystrophy Type 1 (DM1) is a rare genetic neuromuscular condition that can affect multiple organs and varies widely in how it presents. DM1 is the most common form of adult-onset muscular dystrophy, with an estimated prevalence of approximately 1-5 per 10,000 people. In Spain, the condition shows notable regional differences, making it especially important to understand its characteristics within the population.
The aim of this study is to support a research initiative designed to better characterise DM1. We are developing a comprehensive national registry, collecting patient-reported information, clinical data and omics data that will improve our understanding of the disease and help identify individuals who may be eligible for clinical trials.
Interested in participating?
Request InfoAll sexes
Observational
Hospitals within the DM1 network, Multiple Locations, Andalusia, Spain
The DM1-Hub Patient Registry (https://www.dm1spain.com/) aims to recruit individuals living in Spain with a confirmed genetic diagnosis of myotonic dystrophy type 1 (DM1). Participants may be referred by healthcare professionals or patient organizations. They may also learn about the registry through outreach activities, informational materials, collaborations with national and local patient associations, DM1-Hub events, or through their own online searches.
After completing the informed consent process with their neurologist, participants are connected with the DM1-Hub patient support staff assigned to their hospital. An appointment is scheduled, and all the data collected is entered into the REDCap database.
The objective of this study is to establish a Natural History Patient Registry for individuals with DM1 in Spain. Participants will be invited to take part in follow-up assessments to support the characterization of disease progression over time. A parallel control group will also be recruited to facilitate biomarker discovery and improve understanding of factors associated with disease prognosis.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patient Registry
Time frame: 1 year, year 1
Long-read genomic sequencing analyses encompassing CTG expansion characterization and whole-genome genetic and epigenetic profiling.
Time frame: 1 year, year 1
Biomarker evaluation
Time frame: 2 years, year 1
IQ, memory, attention, language
Time frame: 1 year, year 1
Video Hand Opening Time, clinical measure for Myotonic Dystrophy (DM1) tracking hand reopening speed
Time frame: 1 year, year 1
The Muscular Impairment Rating Scale is a 5-point ordinal clinical scale used to evaluate the severity of muscular impairment in patients with myotonic dystrophy.
Scores range from 1 (minimal or no impairment) to 5 (severe muscle impairment). Higher scores indicate worse functional impairment.
Time frame: 1 year, year 1
Hand grip strength is assessed as a measure of upper limb muscle strength using a hand-held dynamometer. Grip strength is measured separately in the dominant and non-dominant hand, and recorded in kilograms (kg).
For each hand, three consecutive attempts are performed, alternating between hands to minimize fatigue. The maximum value (best of three attempts) for each hand is recorded and used for analysis.
Higher values indicate better muscle strength and functional outcome, while lower values reflect greater muscular impairment.
Time frame: 1 year, year 1
Six-Minute Walk Test
Time frame: 1 year, year 1
10-meter Walk/Run Test
Time frame: 1 year, year 1
30-Second Chair Stand Test
Time frame: 1 year, year 1
Forced Vital Capacity (L)
Time frame: 1 year, year 1
The following ECG-derived parameters and abnormalities are recorded:
All measurements are extracted from the ECG tracing according to standard clinical practice.
Higher PR or QRS durations and the presence of conduction abnormalities or arrhythmias indicate greater cardiac involvement, while normal values and absence of abnormalities indicate preserved cardiac electrical function.
Time frame: 1 year, year 1
Body Mass Index
Time frame: 1 year, year 1
Collection of gynecological clinical history and relevant reproductive health events for participants who opt to provide this information.
Time frame: 1 year, year 1
Collection of participant-reported gastrointestinal symptoms and related clinical information.
Time frame: 1 year, year 1
Myotonia severity is assessed using the Myotonia Behaviour Scale (MBS), a clinician-reported ordinal scale that evaluates the functional impact of myotonia-related muscle stiffness on daily activities.
The scale ranges from 0 to 5, with higher scores indicating greater severity and functional interference due to myotonia:
0: No muscle stiffness
Lower scores reflect minimal or absent myotonia, while higher scores reflect greater functional impairment due to myotonia.
Time frame: 1 year, year 1
Global disability is assessed using the Modified Rankin Scale (mRS), a widely used ordinal scale measuring the degree of disability or dependence in daily activities.
The scale ranges from 0 to 6, with higher scores indicating greater disability or death:
0: No symptoms
Time frame: 1 year, year 1
INQoL (Individualized Neuromuscular Quality of Life Questionnaire)
Time frame: 1 year, year 1
FSS (Fatigue Severity Scale )
Time frame: 1 year, year 1
MEDAS-14 (Mediterranean Diet Adherence Screener)
Time frame: 1 year, year 1
DSS (Daytime Sleepiness Scale)
Time frame: 1 year, year 1
AES (Apathy Evaluation Scale)
Time frame: 1 year, year 1
IPAQ (International Physical Activity Questionnaire)
Time frame: 1 year, year 1
MHI-5 (Mental Health Inventory)
Contact information is provided by the study sponsor or research team.
Alvaro S Larran Mottino, Ph.D.
CONTACT
Gisela Nogales Gadea, Ph.D.
CONTACT
(+34) 93 554 3050
Fundació Institut Germans Trias i Pujol
Other
Creación de un Nodo Integral Para la Distrofia Miotónica Tipo 1 en España: Registro clínico, Mapas genómicos, epigenómicos y proteómicos (DM1-Hub)
Acronym: DM1-Hub
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07008469
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DM1
Los Angeles, California, United States
View Trial DetailsNCT07700225
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DM1
Richmond, Virginia, United States
View Trial DetailsNCT02398786
Congenital Myotonic Dystrophy, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Oakland, California, United States
View Trial DetailsNCT05027269
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DM1
Los Angeles, California, United States
View Trial Details